Triheptanoin
Triheptanoin Uses, Dosage, Side Effects, Food Interaction and all others data.
Triheptanoin is a source of heptanoate fatty acids, which can be metabolized without the enzymes of long chain fatty acid oxidation. In clinical trials, patients with long chain fatty acid oxidation disorders (lc-FAODs) treated with triheptanoin are less likely to develop hypoglycemia, cardiomyopathy, rhabdomyolysis, and hepatomegaly. Complications in lc-FAOD patients are reduced from approximately 60% to approximately 10% with the addition of triheptanoin.
Triheptanoin was granted FDA approval on 30 June 2020.
Triheptanoin is a source of medium chain fatty acids for patients with lc-FAODs. It has a moderate duration of action and a wide therapeutic window. Patients should be counselled regarding the risk of feeding tube dysfunction and intestinal malabsorption due to pancreatic insufficiency.
Trade Name | Triheptanoin |
Availability | Prescription only |
Generic | Triheptanoin |
Triheptanoin Other Names | Glycerol triheptanoate, Glyceryl triheptanoate, Trienanthoin, Triheptanoic glyceride, Triheptanoin, Triheptylin, Trioenanthoin |
Related Drugs | Dojolvi |
Weight | 100% |
Type | Oral liquid |
Formula | C24H44O6 |
Weight | Average: 428.61 Monoisotopic: 428.313789137 |
Protein binding | Triheptanoin is approximately 80% protein bound in plasma, likely serum albumin. |
Groups | Approved, Investigational |
Therapeutic Class | |
Manufacturer | |
Available Country | United States |
Last Updated: | September 19, 2023 at 7:00 am |
Uses
Triheptanoin is triheptanoin is a medium chain triglyceride indicated to provide calories and fatty acids to treat long chain fatty acid oxidation disorders.
Triheptanoin is a medium chain triglyceride indicated to provide calories and fatty acids to treat long chain fatty acid oxidation disorders (lc-FAODs).
Triheptanoin is also used to associated treatment for these conditions: Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
How Triheptanoin works
Triheptanoin is a source of heptanoate fatty acids, which can be metabolized without the enzymes of long chain fatty acid oxidation. In clinical trials, patients with lc-FAODs treated with triheptanoin experienced improvements in hypoglycemia, cardiomyopathy, and rhabdomyolysis.
Food Interaction
- Take with food. Take triheptanoin with food, liquid, or formula.
Elimination Route
A single 0.3 g/kg dose of triheptanoin reaches a Cmax of 178.9 µmol/L, with a Tmax 0.5 h, and an AUC of 336.5 µmol*h/L. A single 0.4 g/kg dose of triheptanoin reaches a Cmax of 259.1 µmol/L, with a Tmax 0.8 h, and an AUC of 569.1 µmol*h/L.
Half Life
Due to multiple peak concentrations of the heptanoate metabolite, the half life of triheptanoin could not be determined.
Clearance
A single dose of 0.3 g/kg results in a mean apparent clearance of 6.05 L/h/kg for heptanoate. A single dose of 0.4 g/kg results in a mean apparent clearance of 4.31 L/h/kg for heptanoate.
Elimination Route
Triheptanoin is minimally eliminated in the urine.
Innovators Monograph
You find simplified version here Triheptanoin